ETFMG Treatments Testing and Advancements ETF (GERM) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the ETFMG Treatments Testing and Advancements ETF stock forecast from 0 analysts, the average analyst target price for ETFMG Treatments Testing and Advancements ETF is not available over the next 12 months. ETFMG Treatments Testing and Advancements ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ETFMG Treatments Testing and Advancements ETF is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, ETFMG Treatments Testing and Advancements ETF’s stock price was USD 16.54. ETFMG Treatments Testing and Advancements ETF’s stock price has changed by -6.55% over the past week, -8.92% over the past month and -24.13% over the last year.
No recent analyst target price found for ETFMG Treatments Testing and Advancements ETF
No recent average analyst rating found for ETFMG Treatments Testing and Advancements ETF
Company Overview ETFMG Treatments Testing and Advancements ETF
Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified. Read Less
Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and c...Read More
N/A
N/A
N/A
N/A
USD
USA
N/A
N/A
N/A
0.68 %
Adjusted Closing Price for ETFMG Treatments Testing and Advancements ETF (GERM)
Loading...
Unadjusted Closing Price for ETFMG Treatments Testing and Advancements ETF (GERM)
Loading...
Share Trading Volume for ETFMG Treatments Testing and Advancements ETF Shares
Loading...
Compare Performance of ETFMG Treatments Testing and Advancements ETF Shares
Frequently Asked Questions About ETFMG Treatments Testing and Advancements ETF (GERM) Stock
Stock Target Advisor's fundamental analysis for ETFMG Treatments Testing and Advancements ETF's stock is Very Bearish.
GERM stock's dividend yield is 1.48%.
Our analysis grades GERM stock's dividend yield at F. This means that GERM stock's dividend yield is above 36% of the stocks in the Others sector in the NYE exchange.
Based on this GERM may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on GERM's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on GERM's stock to indicate if its overvalued.
The last closing price of GERM's stock was USD 16.54.
The most recent market capitalization for GERM is USD 0.01B.
Unfortunately we do not have enough analyst data on GERM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ETFMG Treatments Testing and Advancements ETF's stock.
Sorry, we do not have any data on the number of employees for ETFMG Treatments Testing and Advancements ETF.
Sorry we do not have any infomation available on ETFMG Treatments Testing and Advancements ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GERM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
